MIST · Milestone Pharmaceuticals Inc. Common Shares
View on chartInsiders & Stakes
| RTW INVESTMENTS, LP 10% Owner | ▼ Sell | Other | 3,256,102 Shares held | 3/22/2023 | View profile |
| Joseph Oliveto President and CEO | ▼ Sell | Open Market | 446,244 Shares held | 4/16/2026 | View profile |
| Lorenz Muller Chief Commercial Officer | ▼ Sell | Open Market | 205,406 Shares held | 1/26/2026 | View profile |
| David Bharucha Chief Medical Officer | ▼ Sell | Open Market | 113,181 Shares held | 1/26/2026 | View profile |
| Joseph C. Papa President and CEO | ▲ Buy | Grant | 100,000 Shares held | 7/11/2025 | View profile |
| Amit Hasija CFO & EVP of Corp. Development | ▼ Sell | Open Market | 99,848 Shares held | 1/26/2026 | View profile |
| TRUEX PAUL F Director | ▲ Buy | Open Market | 81,780 Shares held | 5/31/2022 | View profile |
| Robert James Wills Director | ▲ Buy | Grant | 65,000 Shares held | 7/11/2025 | View profile |
| Jeffrey Edward Nelson Chief Operating Officer | ▼ Sell | Open Market | 49,848 Shares held | 1/26/2026 | View profile |
| Debra K. Liebert Director | ▲ Buy | Grant | 16,793 Shares held | 7/11/2025 | View profile |
| Michael John Tomsicek Director | ▲ Buy | Open Market | 15,000 Shares held | 10/19/2022 | View profile |
| Pasternak Richard C Director | ▲ Buy | Open Market | 10,000 Shares held | 10/20/2022 | View profile |
Transaction History
| Joseph Oliveto | ▼ Sell | Open Market | 36,500 | $82K | 4/16/2026 |
| Jeffrey Edward Nelson | ▲ Buy | Option Exercise | 20,100 | — | 1/26/2026 |
| Jeffrey Edward Nelson | ▼ Sell | Open Market | 12,245 | $24K | 1/26/2026 |
| Lorenz Muller | ▲ Buy | Option Exercise | 20,100 | — | 1/26/2026 |
| Lorenz Muller | ▼ Sell | Open Market | 11,180 | $22K | 1/26/2026 |
| Amit Hasija | ▲ Buy | Option Exercise | 20,100 | — | 1/26/2026 |
| Amit Hasija | ▼ Sell | Open Market | 12,245 | $24K | 1/26/2026 |
| Joseph Oliveto | ▲ Buy | Option Exercise | 66,600 | — | 1/26/2026 |
| Joseph Oliveto | ▼ Sell | Open Market | 34,523 | $67K | 1/26/2026 |
| David Bharucha | ▼ Sell | Open Market | 12,245 | $24K | 1/26/2026 |
| David Bharucha | ▲ Buy | Option Exercise | 20,100 | — | 1/26/2026 |
| Joseph Oliveto | ▼ Sell | Open Market | 43,000 | $97K | 1/8/2026 |
| Joseph Oliveto | ▼ Sell | Open Market | 500 | $1K | 1/7/2026 |
| Lorenz Muller | ▼ Sell | Open Market | 53,566 | $124K | 12/15/2025 |
| Amit Hasija | ▼ Sell | Open Market | 58,007 | $135K | 12/15/2025 |
| Joseph Oliveto | ▼ Sell | Open Market | 133,054 | $309K | 12/15/2025 |
| Jeffrey Edward Nelson | ▼ Sell | Open Market | 58,007 | $135K | 12/15/2025 |
| David Bharucha | ▼ Sell | Open Market | 58,007 | $135K | 12/15/2025 |
| Lorenz Muller | ▲ Buy | Grant | 100,000 | — | 12/12/2025 |
| Amit Hasija | ▲ Buy | Grant | 100,000 | — | 12/12/2025 |
| Joseph Oliveto | ▲ Buy | Grant | 280,000 | — | 12/12/2025 |
| Jeffrey Edward Nelson | ▲ Buy | Grant | 100,000 | — | 12/12/2025 |
| David Bharucha | ▲ Buy | Grant | 100,000 | — | 12/12/2025 |
| Lorenz Muller | ▼ Sell | Gift | 25,000 | $0 | 12/9/2025 |
| Debra K. Liebert | ▲ Buy | Grant | 16,666 | — | 7/11/2025 |
| Amit Hasija | ▲ Buy | Grant | 50,000 | — | 7/11/2025 |
| Robert James Wills | ▲ Buy | Grant | 50,000 | — | 7/11/2025 |
| David Bharucha | ▲ Buy | Grant | 53,333 | — | 7/11/2025 |
| Joseph Oliveto | ▲ Buy | Grant | 66,666 | — | 7/11/2025 |
| Lorenz Muller | ▲ Buy | Grant | 66,666 | — | 7/11/2025 |
| Joseph C. Papa | ▲ Buy | Grant | 100,000 | — | 7/11/2025 |
| RTW INVESTMENTS, LP | ▼ Sell | Other | 1,059,000 | — | 3/22/2023 |
| David Bharucha | ▲ Buy | Open Market | 7,000 | $33K | 12/5/2022 |
| David Bharucha | ▲ Buy | Open Market | 3,000 | $15K | 12/1/2022 |
| Debra K. Liebert | ▲ Buy | Open Market | 4,000 | $21K | 10/21/2022 |
| Debra K. Liebert | ▲ Buy | Open Market | 10,000 | $53K | 10/20/2022 |
| Pasternak Richard C | ▲ Buy | Open Market | 10,000 | $52K | 10/20/2022 |
| Robert James Wills | ▲ Buy | Open Market | 15,000 | $74K | 10/19/2022 |
| Michael John Tomsicek | ▲ Buy | Open Market | 15,000 | $80K | 10/19/2022 |
| Debra K. Liebert | ▼ Sell | Other | 127 | $0 | 9/14/2022 |
| RTW INVESTMENTS, LP | ▲ Buy | Open Market | 1,557,346 | $13.6M | 9/7/2022 |
| RTW INVESTMENTS, LP | ▼ Sell | Open Market | 1,557,346 | $13.6M | 9/7/2022 |
| TRUEX PAUL F | ▲ Buy | Option Exercise | 8,016 | $9K | 5/31/2022 |
| TRUEX PAUL F | ▲ Buy | Option Exercise | 45,072 | $69K | 5/31/2022 |
| TRUEX PAUL F | ▲ Buy | Option Exercise | 22,870 | $35K | 5/31/2022 |
| TRUEX PAUL F | ▲ Buy | Option Exercise | 822 | $2K | 5/31/2022 |
| TRUEX PAUL F | ▲ Buy | Open Market | 5,000 | $28K | 5/31/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Milestone Enrolls First Canadian Participant in Phase 3 AFib Trial
Milestone Pharmaceuticals reported that the first Canadian participant has been enrolled in its ReVeRA‑301 Phase 3 trial of the epiripamil nasal spray for atrial fibrillation with rapid ventricular response. The enrollment marks a key step toward the pivotal study that will evaluate the drug’s efficacy and safety in a larger population. The company’s progress in this trial could influence future regulatory decisions and market perception of the product.
Milestone Enrolls First Canadian Participant in Phase 3 AFib Trial. Milestone Pharmaceuticals reported that the first Canadian participant has been enrolled in its ReVeRA‑301 Phase 3 trial of the epiripamil nasal spray for atrial fibrillation with rapid ventricular response. The enrollment marks a key step toward the pivotal study that will evaluate the drug’s efficacy and safety in a larger population. The company’s progress in this trial could influence future regulatory decisions and market perception of the product.